Our knowledge and understanding of allergic diseases of the respiratory tract has improved to a point where new therapies are being developed for patient benefit. Inflammation and Allergy Drug Design explains the biologic science that underpins the pathophysiology of asthma and related disorders, as well as their mechanisms. This authoritative guide consists of 25 chapters, each detailing the cutting-edge developments in a particular field. It is divided into three parts, covering cytokines, chemokines, grow factors and mediators. This book allows immunologists, allergologists and researchers in the pharmaceutical industry to learn and appreciate the target biology in drug development. It also provides medical and pharmaceutical postgraduate students and clinicians with a basic understanding of allergic diseases in the respiratory tract.
H4 R is the newest member of the histamine receptor family, which was discovered about twelve years ago. It is considered a very promising drug target. The effort to improve the pharmacokinetic properties of the currently available H4 R ligands is reflected in a steadily growing number of scientific publications and patent applications. Preclinical data strongly confirms the need for novel potent H4 R ligands to explore their therapeutic value in allergy, inflammation, autoimmune disorders, and possibly, cancer. Readers will be provided with extensive knowledge on histamine metabolism, as well as cellular histamine transport, storage and release, effects of histamine and histamine receptor ligands, with particular attention to the H4 R, on inflammatory cells including mast cells, basophils, eosinophils, neutrophils, macrophages, dendritic cells, and T cells. The present knowledge on the regulatory role of histamine and the therapeutic exploitation of histamine receptor ligands in atopic diseases, with emphasis on human and animal models of asthma, allergic dermatitis and pruritus are discussed.
Topics include: Introduction- Immunopathophysiology and Classification of Ocular Allergy", "OcularMast CDermatologicdisorders of the Eyelidsells and Mediators","SeasonalAllergic Conjunctivitis&Perennial Allergic Conjunctivitis","VernalKeratoconjunctivitis","GiantPapillary Conjunctivitis","Dermatologicdisorders of the Eyelids","ContactDermatitis of the Eyelids","AutoimmuneDisorders of the Anterior Surface","PediatricConcerns of Ocular Inflammation","ContactLens","OcularAllergy Treatment","Adverse(Allergic) Effects of GlaucomaMedications"
Extensive experimentation and high failure rates are a well-recognised downside to the drug discovery process, with the resultant high levels of inefficiency and waste producing a negative environmental impact. Sustainable and Green Approaches in Medicinal Chemistry, Second Edition reveals how medicinal chemistry can play a direct role in addressing this issue. After providing essential context to the growth of green chemistry in relation to drug discovery, the book goes on to identify a broad range of practical techniques and useful insights, revealing how medicinal chemistry techniques can be used to improve efficiency, mitigate failure and increase the environmental benignity of the entire drug discovery process. Drawing on the knowledge of a global team of experts, Sustainable and Green Approaches in Medicinal Chemistry 2e encourages the growth of green medicinal chemistry, and supports medicinal chemists, drug discovery researchers, pharmacologists and all those in related fields across both academia and industry in integrating these approaches into their own work. This first volume of the second edition covers synthesis methods following green chemistry principles, contributing to sustainability by saving energy, using lesser toxic reagents/solvents/catalysts and environmentally benign sources including plants and agricultural materials. - Highlights the need for the adoption of sustainable and green chemistry pathways in drug development - Reveals risk factors associated with the drug development process and the ways sustainable approaches can help address these factors - Identifies novel and cost effective green medicinal chemistry approaches for improved efficiency and sustainability
Dieses Fachbuch erläutert die molekularen Grundlagen von Entzündungen, spannt den Bogen zu Infektionskrankheiten und den Zusammenhang zwischen Entzündungen und chronischen Erkrankungen, behandelt abschließend den Heilungsprozess und zeigt Therapiemöglichkeiten.
The year 2010 marks the centennial for the identification of histamine and the first glimpse of its many physiological functions. From these initial findings a rich tapestry of research has uncovered roles for histamine in almost every physiological process with new findings emerging every year. These diverse roles of histamine have made for fertile ground for the discovery of novel therapeutics, and these drugs have been so successful that the term “antihistamine” has entered the common lexicon. This volume is an attempt to give a snapshot in time as to the current understanding of the role of histamine in just one important therapeutic area—inflammation. The first three chapters provide some background context for the rest of the book starting out with a historical perspective by Figueroa and Shankley. Bongers et al provide an overview of the pharmacology of the four histamine receptors and the chapter by Hiroshi Ohtsu describes how histamine is synthesized as well as the insights derived from mice where this synthesis is disrupted. The next several chapters discuss disease areas where histamine is known to be involved. Chapter 4 by Thomas Taylor-Clark outlines the role of histamine in allergic rhinitis, an area were antihistamines are commonly used. This is also true for ocular allergy as discussed by Ohbayashi et al. Both of these chapters highlight aspects of these conditions that are still not well-controlled and suggest the utility of new antihistamines targeting other histamine receptors.
Over the past 20 years, public concerns have grown in response to the apparent rising prevalence of food allergy and related atopic conditions, such as eczema. Although evidence on the true prevalence of food allergy is complicated by insufficient or inconsistent data and studies with variable methodologies, many health care experts who care for patients agree that a real increase in food allergy has occurred and that it is unlikely to be due simply to an increase in awareness and better tools for diagnosis. Many stakeholders are concerned about these increases, including the general public, policy makers, regulatory agencies, the food industry, scientists, clinicians, and especially families of children and young people suffering from food allergy. At the present time, however, despite a mounting body of data on the prevalence, health consequences, and associated costs of food allergy, this chronic disease has not garnered the level of societal attention that it warrants. Moreover, for patients and families at risk, recommendations and guidelines have not been clear about preventing exposure or the onset of reactions or for managing this disease. Finding a Path to Safety in Food Allergy examines critical issues related to food allergy, including the prevalence and severity of food allergy and its impact on affected individuals, families, and communities; and current understanding of food allergy as a disease, and in diagnostics, treatments, prevention, and public policy. This report seeks to: clarify the nature of the disease, its causes, and its current management; highlight gaps in knowledge; encourage the implementation of management tools at many levels and among many stakeholders; and delineate a roadmap to safety for those who have, or are at risk of developing, food allergy, as well as for others in society who are responsible for public health.
Recent studies show that the number of people suffering with seasonal allergies has been skyrocketing and is expected to continue increasing into the foreseeable future. And in the United States alone, 65 million people suffer with seasonal allergies on a regular basis. In Dr. Psenka's Seasonal Allergy Solution, author and naturopathic physician Dr. Jonathan Psenka tells readers they can—and should—aim for a cure. Readers will discover how people often attempt to manage the symptoms of their seasonal allergies with pills, sprays, drops, and even painful shots. But very few of these medications treat the cause, so symptoms are likely to return year after year. Dr. Psenka has developed a highly detailed, fourstep plan, so readers will finally target the root cause of their seasonal allergies and be free of allergy medication. By following Dr. Psenka's advice on how to use natural remedies before, during, and after allergy season, readers can finally wave good-bye to their pesky runny noses and scratchy throats.
Quinone-Based Compounds in Drug Discovery: Trends and Applications provides a comprehensive and up-to-date overview of the latest advances in the field of drug discovery using quinone-based materials. The book covers various aspects of quinone-based materials such as their synthesis, characterization, and applications in drug discovery, consolidating current research. It introduces quinones in the pharmacology context and then describes current developments in drugs for key diseases and conditions. Final chapters deal with the regulatory and commercial framework to take quinone-based drugs to the market. This book will benefit a wide range of readers, including researchers, scientists, and graduate students in the field of drug discovery. Chemists and biochemists will also benefit from the contents of this book. - Covers various aspects of quinone-based materials, including their synthesis, characterization, and applications in drug discovery - Includes specific chapters on antibiotic, neuroprotective, anticancer, antioxidant, and cardio protection through the action of quinones - Incorporates information on the regulatory, intellectual property, commercialization, and clinical development of quinone-based drugs
The Organic Chemistry of Drug Design and Drug Action, Third Edition, represents a unique approach to medicinal chemistry based on physical organic chemical principles and reaction mechanisms that rationalize drug action, which allows reader to extrapolate those core principles and mechanisms to many related classes of drug molecules. This new edition includes updates to all chapters, including new examples and references. It reflects significant changes in the process of drug design over the last decade and preserves the successful approach of the previous editions while including significant changes in format and coverage. This text is designed for undergraduate and graduate students in chemistry studying medicinal chemistry or pharmaceutical chemistry; research chemists and biochemists working in pharmaceutical and biotechnology industries. - Updates to all chapters, including new examples and references - Chapter 1 (Introduction): Completely rewritten and expanded as an overview of topics discussed in detail throughout the book - Chapter 2 (Lead Discovery and Lead Modification): Sections on sources of compounds for screening including library collections, virtual screening, and computational methods, as well as hit-to-lead and scaffold hopping; expanded sections on sources of lead compounds, fragment-based lead discovery, and molecular graphics; and deemphasized solid-phase synthesis and combinatorial chemistry - Chapter 3 (Receptors): Drug-receptor interactions, cation-p and halogen bonding; atropisomers; case history of the insomnia drug suvorexant - Chapter 4 (Enzymes): Expanded sections on enzyme catalysis in drug discovery and enzyme synthesis - Chapter 5 (Enzyme Inhibition and Inactivation): New case histories: - for competitive inhibition, the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib and Abelson kinase inhibitor, imatinib - for transition state analogue inhibition, the purine nucleoside phosphorylase inhibitors, forodesine and DADMe-ImmH, as well as the mechanism of the multisubstrate analog inhibitor isoniazid - for slow, tight-binding inhibition, the dipeptidyl peptidase-4 inhibitor, saxagliptin - Chapter 7 (Drug Resistance and Drug Synergism): This new chapter includes topics taken from two chapters in the previous edition, with many new examples - Chapter 8 (Drug Metabolism): Discussions of toxicophores and reactive metabolites - Chapter 9 (Prodrugs and Drug Delivery Systems): Discussion of antibody–drug conjugates
